PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

BMC Cancer

Volumn 12, Issue , 2012, Pages

  McKeage, Mark J ^a,g   Jameson, Michael B ^b   Ramanathan, Ramesh K ^c   Rajendran, Joseph ^d   Gu, Yongchuan ^a   Wilson, William R ^a   Melink, Teresa J ^e   Tchekmedyian, N S ^f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

^c Virginia G Piper Cancer Center and TGEN   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Proacta Inc   (United States)

^f Pacific Shores Medical Group   (United States)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PR 104; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; DEATH; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; QT PROLONGATION; RESPIRATORY TRACT INFECTION; SARCOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CELL HYPOXIA; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TAXOIDS;

EID: 84867748471     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-496     Document Type: Article

References (29)

1. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Canc 2011, 11(6):393-410.
2. Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Canc Res 2011, 71(17):5923-5931.
3. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Canc Res 2010, 70(4):1573-1584.
4. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: Relationships to hypoxia, bioreductive metabolism and cytotoxicity. Canc Res 2009, 69(9):3884-3891.
5. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Canc Res 2007, 13(13):3922-3932.
6. Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su JC, Li D, Wilson WR, Dachs GU, Patterson AV. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol Pharmacol 2012, 81(1):31-40. 10.1124/mol.111.073759, 21984255.
7. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Canc Chemother Pharmacol 2010, 65(4):791-801.
8. McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer 2011, 11(1):432. 10.1186/1471-2407-11-432, 3205073, 21982454.
9. Noble S, Goa KL. Gemcitabine - a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997, 54(3):447-472. 10.2165/00003495-199754030-00009, 9279506.
10. Sanofi-Aventis US. Taxotere (docetaxel) full prescribing information 2011, 08807. Bridgewater NJ, Bridgewater NJ, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020449s064lbl.pdf.
11. Jang SH, Wientjes MG, Au JLS. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs 2001, 19(2):113-123. 10.1023/A:1010662413174, 11392446.
12. Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Canc Res 2004, 64(18):6537-6541.
13. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Gerald GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998, 46(3):229-237. 10.1016/S0167-8140(97)00186-2, 9572615.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid Tumors. J Natl Canc Inst 2000, 92(3):205-216.
15. Gu Y, Wilson WR. Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(27):3181-3186. 10.1016/j.jchromb.2009.08.009, 19709934.
16. Atwell GJ, Denny WA. Synthesis of H-3- and H-2(4)-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)carbonyl) anilino)ethyl methanesulfonate (PR-104). J Label Compd Radiopharm 2007, 50(1-2):7-12.
17. Gu Y, Atwell GJ, Wilson WR. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans. Drug Metab Dispos 2010, 38(3):498-508. 10.1124/dmd.109.030973, 20019245.
18. Gu Y, Tingle MD, Wilson WR. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-Glucuronosyltransferases, and implications for therapy. J Pharmacol Exp Ther 2011, 337(3):692-702. 10.1124/jpet.111.180703, 21427202.
19. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999, 17(3):958-967.
20. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Canc Res 2004, 10(6):1976-1983.
21. Extra JM, Rousseau F, Bruno R, Clavel M, Lebail N, Marty M. Phase-I and pharmacokinetic study of Taxotere(RP-56976, NSC-628503) given as a short intravenous-infusion. Canc Res 1993, 53(5):1037-1042.
22. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. A phase-I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9(3):491-498.
23. Fogli S, Danesi R, Braud FD, Pas TD, Curigliano G, Giovannetti E, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol 2001, 12(11):1553-1559. 10.1023/A:1013133415945, 11822754.
24. Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating-agents used in the treatment of hematological malignancies. Blood Rev 1992, 6(3):163-173. 10.1016/0268-960X(92)90028-O, 1422285.
25. Patel K, Choy SSF, Hicks KO, Melink TJ, Holford NHG, Wilson WR. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Canc Chemother Pharmacol 2011, 67(5):1145-1155.
26. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19(2):535-542.
27. Borad M, Mita A, Infante J, Chiorean EG, Vlahovic G, Armstrong A, Traynor AM, Schelman W, Langmuir V, Eng C. Complete phase Ib study of TH-302 in combination with gemcitabine (G), docetaxel (D) or pemetrexed (P). Ann Oncol 2010, 21:172-172.
28. Ryan D, Reddy S, Bahary N, Uronis H, Sigal DS, Cohn A, Schelman WR, Chiorean EG, Rosen PJ, Ulrich B, et al. Phase II study of gemcitabine + TH-302 vs gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer. Ann Oncol 2012, 23:8-8.
29. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, et al. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. Clin Canc Res 2011, 17(9):2997-3004.